Stay updated on Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.

Latest updates to the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page
- Check6 days agoChange DetectedThe page revision has been updated from v3.6.0 to v3.6.2, reflecting an internal update to the page. This change does not affect the study details, eligibility criteria, or user-facing features.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedNew navigation links were added to help users find who can join, contact information, how to read a study record, common questions, and how to join, and a version stamp 'Revision: v3.6.0' was introduced. The existing 'Intervention / Treatment' label was updated to 'Intervention/Treatment' to standardize terminology.SummaryDifference0.5%

- Check28 days agoChange DetectedThe study page was updated to include a new revision tag (v3.5.5) and show recent update dates (2026-06-04, 2026-06-05). This indicates the record has been refreshed or versioned recently for tracking purposes.SummaryDifference0.3%

- Check42 days agoChange DetectedTwo new update entries dated 2026-05-20 and 2026-05-22 were added to the study record's update history. Entries dated 2026-05-06 and 2026-05-07 were removed from the history, altering the visible timeline of recent changes.SummaryDifference0.2%

- Check50 days agoChange DetectedThe page records were updated to Revision: v3.5.4, replacing the previous Revision: v3.5.3, indicating a newer release of the document.SummaryDifference0.1%

- Check57 days agoChange DetectedThe updates log gained two new post dates (May 7 and May 6, 2026) and older dates were removed, altering the sequence of posted information in the study record.SummaryDifference0.2%

Stay in the know with updates to Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in EBV+ Lymphoproliferative Disorders Clinical Trial page.